Difference between revisions of "Estrogen receptor"
Jump to navigation
Jump to search
(create) |
|||
| Line 7: | Line 7: | ||
*[[Breast carcinoma]] - most. | *[[Breast carcinoma]] - most. | ||
**[[Ductal carcinoma in situ]] - most. | **[[Ductal carcinoma in situ]] - most. | ||
**[[Invasive lobular | **[[Invasive lobular carcinoma]] - all. | ||
**[[Invasive ductal carcinoma of breast]] - most. | **[[Invasive ductal carcinoma of the breast]] - most. | ||
*[[Endometrial carcinoma]]s. | *[[Endometrial carcinoma]]s. | ||
Revision as of 20:25, 23 June 2016
Estrogen receptor, abbreviated ER, is a common immunostain.
General
In the context of breast pathology it is a class II IHC test, as it is used for treatment decisions by itself.[1]
Positive
- Breast carcinoma - most.
- Ductal carcinoma in situ - most.
- Invasive lobular carcinoma - all.
- Invasive ductal carcinoma of the breast - most.
- Endometrial carcinomas.
Negative
See also
References
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.